Advertisement
Screener

Bausch Health Companies Inc. (BHC) Overview

Bausch Health Companies Inc. (BHC) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.68; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -3.82; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.48; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.40; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$4.21$4.85$5.60$6.46$7.45$8.592025-11-062026-11-06$4.10$6.09$9.05$13.44$19.97$29.652021-11-082026-11-06$4.10$6.34$9.79$15.13$23.37$36.102016-11-072026-11-06$4.10$10.23$25.50$63.56$158.44$394.952006-11-062026-11-06$0.33$1.38$5.74$23.82$98.93$410.891994-03-292026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$8.19
Previous close
$5.80
Change
$2.39
Change (%)
41.12%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

BHC
-16.56%
S&P 500
(m)

1 year

BHC
-10.32%
S&P 500
(m)

3 years

BHC
-29.43%
S&P 500
(m)

5 years

BHC
-79.39%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.68

-3.90-2.71-1.52-0.330.8631 Mar 2025: estimate (m); actual -0.1631 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.4030 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.4830 Sept 2025(m)31 Mar 2026: estimate (m); actual -3.8231 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.6830 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.68(m)(m)
1 Jan 202631 Mar 2026(m)-3.82(m)(m)
1 Jul 202530 Sept 2025(m)0.48(m)(m)
1 Apr 202530 Jun 2025(m)0.40(m)(m)
1 Jan 202531 Mar 2025(m)-0.16(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 0.42

-2.72-1.89-1.06-0.230.6031 Dec 2021: estimate (m); actual -2.6431 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.6231 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.6231 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.1331 Dec 2024(m)31 Dec 2025: estimate (m); actual 0.4231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)0.42(m)(m)
1 Jan 202431 Dec 2024(m)-0.13(m)(m)
1 Jan 202331 Dec 2023(m)-1.62(m)(m)
1 Jan 202231 Dec 2022(m)-0.62(m)(m)
1 Jan 202131 Dec 2021(m)-2.64(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 2.85B ■ Earnings 0.26B — Profit margin 9.05%

-1.94B-57.4%-0.17B-34.9%1.60B-12.4%3.37B10.0%30 Sept 2025: revenue 2.68B; earnings 0.18B; profit margin 6.68%30 Sept 202531 Dec 2025: revenue 2.80B*; earnings -0.11B*; profit margin -4.01%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 2.52B; earnings -1.42B; profit margin -56.38%31 Mar 202630 Jun 2026: revenue 2.85B; earnings 0.26B; profit margin 9.05%30 Jun 2026

31 Dec 2025 ■ Revenue 10.27B ■ Earnings 0.16B — Profit margin 1.53%

-1.89B-7.8%2.59B-4.3%7.08B-0.9%11.57B2.5%31 Dec 2022: revenue 8.12B; earnings -0.23B; profit margin -2.77%31 Dec 202231 Dec 2023: revenue 8.76B; earnings -0.59B; profit margin -6.76%31 Dec 202331 Dec 2024: revenue 9.63B; earnings -0.05B; profit margin -0.48%31 Dec 202431 Dec 2025: revenue 10.27B; earnings 0.16B; profit margin 1.53%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$8.19(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$8.19High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning BHC

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-13; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-1.10B
Profit margin
-10.12%
Return on assets · 12 month
-4.22%
Index membership
(m)
Employees
20.30K
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
2.29M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-0.17%*
Total return · month
-8.23%*
Total return · quarter
19.57%*
Total return · half year
15.57%*
Total return · year to date
-16.56%*
Total return · 1 year
-10.32%*
Total return · 3 years
-29.43%*
Total return · 5 years
-79.39%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$10.85B
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
-1171.15%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Bausch Health Companies Inc. Overview

View more →

(m)

(m)

SEC CIK
885590
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
(m)
Business address
2150 ST. ELZEAR BLVD. WEST, LAVAL, QUEBEC, H7L 4A8
Fiscal year end
1231
Phone
514-744-6792

Similar stocks

Stock NameCountryMarket CapPE Ratio
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
UroGen Pharma Ltd. (URGN)$2.015B-18.42